What an unloader brace actually does to your knee

The question most patients ask when an unloader brace is first suggested is a reasonable one: does it change anything structurally, or is it simply making the knee feel better? The honest answer is both — and the two effects are directly connected.

The brace works by applying a three-point valgus corrective force across the joint. Rigid shells sit against the thigh and calf, and a corrective strap acts as the opposing point of leverage, bending the knee gently outward to counteract the inward bow that places excess load on the inner (medial) side — the compartment between the lower end of the femur and the upper surface of the tibia. That physical correction measurably opens the medial joint space, shifting body weight toward the healthier outer (lateral) compartment rather than concentrating it on the worn cartilage.

Petersen's 2016 systematic review confirmed that this translates into a reduction in the external knee adduction moment — the rotational force that drives progressive medial overloading. Reduced mechanical stress, in turn, lowers the inflammatory burden on the remaining cartilage, which is why pain relief in this context is not mere masking: it reflects a genuine reduction in the load causing the inflammation in the first place.

The mechanism is entirely mechanical. There are no systemic effects, no recovery period, and it can be stopped at any time — a meaningful advantage when weighing options at this stage of a preservation pathway.

Why varus malalignment concentrates damage on one side

Varus malalignment — the outward bowing of the leg that gives the condition its 'bow-legged' description — shifts the body's mechanical axis medially, so that the line of force passing through the limb during walking falls inside the knee rather than through its centre. The consequence is straightforward: the medial tibio-femoral compartment bears a disproportionate share of load with every step.

The external knee adduction moment (KAM) is the quantitative measure of this imbalance — the rotational force that pushes the inner joint surfaces together during the stance phase of gait. Higher KAM values correlate with faster cartilage degradation in the medial compartment, making it both a marker of disease severity and a direct mechanical target for treatment. Petersen's 2016 systematic review confirmed that unloader bracing reduces the KAM in medial compartment OA, directly opposing the principal driver of progression. Moyer et al.'s 2015 meta-analysis extended that finding, reporting moderate-to-high effect sizes across the range of joint load changes associated with valgus bracing — giving the biomechanical case for offloading a quantitative foundation.

Beyond load redistribution, reducing pathological compressive stress appears to improve the biochemical environment of the remaining cartilage matrix. In practical terms, patients with swelling driven partly by mechanical overload often notice a reduction in joint puffiness alongside pain relief — consistent with attenuation of intra-articular oedema. This mechanobiological effect is plausible and supported by early evidence, though it is less firmly established than the load-transfer data.

What clinical studies show about pain, function, and quality of life

Three systematic reviews, spanning 2009 to 2023, build a consistent picture of what patients can expect from an unloader brace in practice.

Ramsey's 2009 synthesis, endorsed by OARSI, placed the recommendation strength for unloader bracing at 76% (95% CI 69%–83%) — specifically for reducing pain, improving stability, and diminishing fall risk in patients with unicompartmental OA and mild-to-moderate instability, a combination that is common in clinical practice. That guideline-level endorsement gives the intervention credibility beyond individual trial results.

Mistry et al.'s 2018 review of 14 studies from the preceding decade found near-universal support across pain, physical function, and quality-of-life endpoints. A 2017 cost-effectiveness analysis cited within that review ranked bracing favourably against total knee replacement on a health-economics basis — and suggested that, for some patients, bracing could remove the need for surgery altogether.

Beck et al. (2023) added a clinically useful temporal dimension: benefits are both immediate, apparent from a patient's first application, and progressive, accumulating over subsequent weeks. This two-phase pattern points to neuromotor adaptation reinforcing the initial mechanical offloading — the brace appears to train the neuromuscular system to sustain load redistribution even when it is not worn.

The controlled study evidence for pain relief, improved stability, and functional gain is therefore substantial. The gap between those results and everyday outcomes is real — and largely explained by one factor: adherence.

The compliance gap — why many patients stop wearing the brace

Squyer et al.'s 2013 survey of 89 patients, followed up 12–40 months after prescription, puts a precise number on that gap. At one year, only 28% were wearing their brace regularly — defined as at least twice a week for at least an hour. By year two, that figure had edged down to 25%. Three in every four patients had, in effect, stopped using an intervention that the clinical evidence supports.

What makes the picture harder to manage is that no baseline clinical or radiographic characteristic reliably identified in advance which patients would persist. Severity of OA, degree of varus alignment, age, weight — none predicted sustained use. That absence of a screening marker means clinicians cannot confidently pre-select who will benefit in routine practice, even when the pathology is well suited to bracing.

Patients themselves cited several reasons for stopping: insufficient symptom relief, discomfort during wear, poor fit, and skin irritation. These are largely practical rather than philosophical objections — which is significant, because most are addressable.

The implication is not that bracing rarely works; the controlled-study evidence reviewed earlier is clear that it does. The implication is that efficacy under study conditions diverges sharply from real-world effectiveness, and bridging that gap requires deliberate effort. Proper fitting at the outset, a gradual wear-in schedule — two hours per day in the first week, building to four hours by week two — and a structured review at four to eight weeks are the points at which poor adherence is most likely to be intercepted. Early reviews can identify fit problems and recalibrate expectations before a patient quietly shelves the device.

Getting fitted, wearing it correctly, and NHS access

Accessing an unloader brace in England is straightforward in some areas and requires persistence in others. NHS physiotherapists can arrange fitting, and models such as the Össur Unloader One are available on the NHS in certain regions. Commissioning is not uniform across England, however: at least one ICB — Bedfordshire, Luton and Milton Keynes — recommended against routine primary-care prescribing of specific offloading braces as recently as 2024. Patients who cannot access a device through a GP or physiotherapy referral may need to pursue it privately.

Once fitted, wearing the brace consistently through the gradual build-up period outlined earlier is what converts the initial mechanical benefit into progressive functional improvement — a process that takes several weeks rather than days.

Fit quality is not a minor consideration. An ill-fitting brace is one of the most commonly cited reasons patients stop wearing the device, and biomechanical effectiveness depends on accurate positioning as much as comfort. Off-the-shelf sizing is rarely adequate; a dedicated clinical or orthotist fitting appointment is worth requesting, and is the point at which most friction around comfort and skin pressure can be resolved early. Minor adverse effects — soft tissue irritation, skin pressure at contact points, and brace migration during activity — are common but generally manageable and typically addressed through fit adjustment rather than abandonment of the device.

Where bracing sits before surgery becomes the conversation

Placing bracing on the treatment map helps answer the question most patients reach eventually: what comes next if the brace is not enough?

Both NICE NG226 (2022) and the OARSI guidelines position unloader bracing within the non-pharmacological management tier — a first-line, non-surgical intervention to be fully explored before any surgical conversation begins. That framing matters: the guidelines are not suggesting bracing as a temporary distraction pending an inevitable operation. They are placing it as a substantive, evidence-backed strategy in its own right, one that addresses the mechanical driver of the condition directly.

If the knee continues to deteriorate despite optimally used bracing, the surgical options in sequence include high tibial osteotomy (HTO) — a bone-realignment procedure that achieves surgically what the brace achieves externally — unicompartmental knee replacement, and ultimately total knee replacement. Each carries a larger procedural footprint and a longer recovery. Bracing does not foreclose any of them; if anything, by slowing compartmental loading and buying time, it may preserve more tissue-level options when a surgical decision eventually has to be made.

The honest clinical question is not whether to use a brace but whether bracing alone is the right preservation strategy for a particular knee at a particular stage. That requires biomechanical evaluation, imaging review, and a frank discussion about trajectory — exactly the kind of assessment a specialist joint-preservation service provides. For patients in London, that evaluation is available at the London Cartilage Clinic on Harley Street; details and consultation bookings are at londoncartilage.com.